Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study.
Lea HoisnardLaura Pina VegasRosemay Dray-SpiraAlain WeillMahmoud ZureikEmilie SbidianPublished in: Annals of the rheumatic diseases (2022)
This study provides reassuring data regarding the risks of MACEs and VTEs in patients initiating a JAKi versus adalimumab, including patients at high risk of cardiovascular diseases.
Keyphrases
- venous thromboembolism
- end stage renal disease
- rheumatoid arthritis
- cardiovascular disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- juvenile idiopathic arthritis
- peritoneal dialysis
- prognostic factors
- emergency department
- direct oral anticoagulants
- electronic health record
- ulcerative colitis
- risk assessment
- coronary artery disease
- metabolic syndrome
- human health
- patient reported